References
- AVYCAZ. (2016). AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206494s002lbl.pdf [last accessed 5 Sep 2019].
- Berkhout J, Melchers MJ, van Mil AC, et al. (2015). Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother 59:2299–304.
- Bhagwat SS, Periasamy H, Takalkar SS, et al. (2019). The novel β-lactam enhancer zidebactam augments the in vivo pharmacodynamic activity of cefepime in a neutropenic mouse lung Acinetobacter baumannii infection model. Antimicrob Agents Chemother 63:e02146–18.
- Bhatia A, Gupta M, Chugh R, Friedland HD. (2016). Zidebactam phase 1 single ascending dose and crossover study in healthy subjects. Poster 2236. Poster Presented at ID Week; 2016 Oct 26–30; New Orleans, LA, USA.
- Bush K. (2018). Game changers: new β-lactamase inhibitor combinations targeting antibiotic resistance in gram-negative bacteria. ACS Infect Dis 4:84–7.
- CDC. (2018). Centers for Disease Control and Prevention. Antibiotic resistance: the global threat. Available at: https://www.cdc.gov/features/antibiotic-resistance-global/index.html [last accessed 5 Sep 2019].
- Dash RP, Rais R, Srinivas NR. (2018). Key pharmacokinetic essentials of fixed-dosed combination products: case studies and perspectives. Clin Pharmacokinet 57:419–26.
- Draenert R, Seybold U, Grützner E, Bogner JR. (2015). Novel antibiotics: are we still in the pre-post-antibiotic era? Infection 43:145–51.
- Giri P, Patel H, Srinivas NR. (2019). Review of clinical pharmacokinetics of avibactam, a newly approved non-β lactam β-lactamase inhibitor drug, in combination use with ceftazidime. Drug Res (Stuttg) 69:245–55.
- H.R.2182. (2011). Generating Antibiotic Incentives Now Act of 2011, 112th Cong (2011–2012). Available at: www.congress.gov/bill/112th-congress/house-bill/2182.
- Högberg LD, Heddini A, Cars O. (2010). The global need for effective antibiotics: challenges and recent advances. Trends Pharmacol Sci 31:509–15.
- Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94.
- Mosley JF, Smith LL, Parke CK, et al. (2016). Ceftazidime-Avibactam (Avycaz): for the treatment of complicated intra-abdominal and urinary tract infections. P T 41:479–83.
- Muller A, Mouton J. (2017). Population pharmacokinetics of zidebactam (WCK 5107), a novel beta-lactam enhancer antibiotic. P1299, 27th ECCMID; 2017 Apr 22–25; Vienna, Austria.
- Srinivas NR. (2017). Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectives. Future Microbiol 12:847–51.
- Srinivas NR. (2019). Combination of flavonoids with azole drugs for fungal infections: key pharmacokinetic challenges. Future Microbiol 14:733–8.
- VABOMERE. (2017). VABOMERE™ (meropenem and vaborbactam) for injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf [last accessed 5 Sep 2019].
- WHO. (2018). Available at: http://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance [last accessed 5 Sep 2019].
- ZERBAXA. (2014). ZERBAXA (ceftolozane/tazobactam) for injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf [last accessed 5 Sep 2019].